Friday, July 10, 2026

Drug profile · INN

dornase alfa

dornase alfa (PULMOZYME) is a dna hydrolytic enzyme. Associated with Hoffmann-La Roche. Current US regulatory status: approved.

FDA: approved TGA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dornase alfa
US status
approved
Class
Route
Patents
0
Programs
0
Data quality
0.81

Quick answer

dornase alfa (PULMOZYME) is a dna hydrolytic enzyme. Associated with Hoffmann-La Roche. Current US regulatory status: approved.

Key facts

INN dornase alfa
Brand PULMOZYME
Mechanism DNA hydrolytic enzyme
Target DNA
Formulation VIAL

Mechanism of action

DNA hydrolytic enzyme

Primary target: DNA

Approval history

Authority Status Date
FDA approved
TGA approved

Related & competitor drugs

  1. acyclovir Human herpesvirus 1 DNA polymerase inhibitor
  2. acyclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  3. azacitidine Antineoplastic and immunomodulating agents (L01)
  4. bleomycin sulfate DNA inhibitor
  5. busulfan Antineoplastic and immunomodulating agents (L01)
  6. capecitabine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is dornase alfa?

dornase alfa (PULMOZYME) is a dna hydrolytic enzyme. Associated with Hoffmann-La Roche. Current US regulatory status: approved.

What is the brand name for dornase alfa?

PULMOZYME is a marketed brand name for dornase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dornase alfa?

dornase alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.